Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Diseases × Lapatinib × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Oesophagogastric Cancer 1 Inflammatory Breast Neoplasms 1 Carcinoma, Ductal, Breast 1 Breast Diseases 1

Interventions

Tamoxifen 1 Letrozole 1 Lapatinib 1 Goserelin 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

RemeGen Co., Ltd.

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡